Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medilac-s plus esomeprazole for functional dyspepsia
ChiCTR2300073021Phase 4Completed
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Apr 2023
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional dyspepsia (FD) comparing Esomeprazole + Medilac-s with Esomeprazole + placebo (2 arms). Primary endpoints: 7-point Global Overall Symptom Scale score at 4 weeks and Fecal microbiota. Started Apr 2023; status: completed.
02
Drugs
bacillus subtilisesomeprazole
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on ChiCTR2300073021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073021.